Literature DB >> 27913632

Intracellular Activation of Complement 3 Is Responsible for Intestinal Tissue Damage during Mesenteric Ischemia.

Abhigyan Satyam1, Lakshmi Kannan1, Naoya Matsumoto1, Mayya Geha1,2, Peter H Lapchak1, Robin Bosse1, Guo-Ping Shi3, Jurandir J Dalle Lucca4, Maria G Tsokos1, George C Tsokos5.   

Abstract

Intestinal ischemia followed by reperfusion leads to local and remote organ injury attributed to inflammatory response during the reperfusion phase. The extent to which ischemia contributes to ischemia/reperfusion injury has not been thoroughly studied. After careful evaluation of intestinal tissue following 30 min of ischemia, we noticed significant local mucosal injury in wild-type mice. This injury was drastically reduced in C3-deficient mice, suggesting C3 involvement. Depletion of circulating complement with cobra venom factor eliminated, as expected, injury recorded at the end of the reperfusion phase but failed to eliminate injury that occurred during the ischemic phase. Immunohistochemical studies showed that tissue damage during ischemia was associated with increased expression of C3/C3 fragments primarily in the intestinal epithelial cells, suggesting local involvement of complement. In vitro studies using Caco2 intestinal epithelial cells showed that in the presence of LPS or exposure to hypoxic conditions the cells produce higher C3 mRNA as well as C3a fragment. Caco2 cells were also noted to produce cathepsins B and L, and inhibition of cathepsins suppressed the release of C3a. Finally, we found that mice treated with a cathepsin inhibitor and cathepsin B-deficient mice suffer limited intestinal injury during the ischemic phase. To our knowledge, our findings demonstrate for the first time that significant intestinal injury occurs during ischemia prior to reperfusion and that this is due to activation of C3 within the intestinal epithelial cells in a cathepsin-dependent manner. Modulation of cathepsin activity may prevent injury of organs exposed to ischemia.
Copyright © 2017 by The American Association of Immunologists, Inc.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27913632     DOI: 10.4049/jimmunol.1502287

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  31 in total

1.  Complement factor H-deficient mice develop spontaneous hepatic tumors.

Authors:  Jennifer Laskowski; Brandon Renner; Matthew C Pickering; Natalie J Serkova; Peter M Smith-Jones; Eric T Clambey; Raphael A Nemenoff; Joshua M Thurman
Journal:  J Clin Invest       Date:  2020-08-03       Impact factor: 14.808

2.  Astrocyte-microglia interaction drives evolving neuromyelitis optica lesion.

Authors:  Tingjun Chen; Vanda A Lennon; Yong U Liu; Dale B Bosco; Yujiao Li; Min-Hee Yi; Jia Zhu; Shihui Wei; Long-Jun Wu
Journal:  J Clin Invest       Date:  2020-08-03       Impact factor: 14.808

3.  Protective Effects of the Complement Inhibitor Compstatin CP40 in Hemorrhagic Shock.

Authors:  Martijn van Griensven; Daniel Ricklin; Stephanie Denk; Rebecca Halbgebauer; Christian K Braun; Anke Schultze; Felix Hönes; Sofia Koutsogiannaki; Alexandra Primikyri; Edimara Reis; David Messerer; Sebastian Hafner; Peter Radermacher; Ali-Reza Biglarnia; Ranillo R G Resuello; Joel V Tuplano; Benjamin Mayer; Kristina Nilsson; Bo Nilsson; John D Lambris; Markus Huber-Lang
Journal:  Shock       Date:  2019-01       Impact factor: 3.454

4.  Intracellular C3 Protects Human Airway Epithelial Cells from Stress-associated Cell Death.

Authors:  Hrishikesh S Kulkarni; Michelle L Elvington; Yi-Chieh Perng; M Kathryn Liszewski; Derek E Byers; Christopher Farkouh; Roger D Yusen; Deborah J Lenschow; Steven L Brody; John P Atkinson
Journal:  Am J Respir Cell Mol Biol       Date:  2019-02       Impact factor: 6.914

Review 5.  Complement and the Regulation of T Cell Responses.

Authors:  Erin E West; Martin Kolev; Claudia Kemper
Journal:  Annu Rev Immunol       Date:  2018-04-26       Impact factor: 28.527

Review 6.  The Complement System and Preeclampsia.

Authors:  Jean F Regal; Richard M Burwick; Sherry D Fleming
Journal:  Curr Hypertens Rep       Date:  2017-10-18       Impact factor: 5.369

Review 7.  Targeting complement-mediated immunoregulation for cancer immunotherapy.

Authors:  Martin Kolev; Maciej M Markiewski
Journal:  Semin Immunol       Date:  2018-02-15       Impact factor: 11.130

8.  The complement C3-C3aR pathway mediates microglia-astrocyte interaction following status epilepticus.

Authors:  Yujia Wei; Tingjun Chen; Dale B Bosco; Manling Xie; Jiaying Zheng; Aastha Dheer; Yanlu Ying; Qian Wu; Vanda A Lennon; Long-Jun Wu
Journal:  Glia       Date:  2020-12-14       Impact factor: 7.452

Review 9.  Aberrant Complement System Activation in Neurological Disorders.

Authors:  Karolina Ziabska; Malgorzata Ziemka-Nalecz; Paulina Pawelec; Joanna Sypecka; Teresa Zalewska
Journal:  Int J Mol Sci       Date:  2021-04-28       Impact factor: 5.923

Review 10.  Context-dependent roles of complement in cancer.

Authors:  Lubka T Roumenina; Marie V Daugan; Florent Petitprez; Catherine Sautès-Fridman; Wolf Herman Fridman
Journal:  Nat Rev Cancer       Date:  2019-10-30       Impact factor: 60.716

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.